First-line nivolumab-ipilimumab in TMB-high NSCLC with was associated with a more than tripled 1-year progression-free survival (PFS) rate compared to platinum-based chemotherapy in the Phase III CheckMate 227 trial (NCT02477826).
What is new in chemotherapy for cancer? Read our chemotherapy blog and learn more about the latest advancements in cytotoxic therapy for several cancers.
Frontline pembrolizumab (KeytrudaⓇ) plus standard platinum-based chemotherapy reduces the risk of death by more than 50% in patients with nonsquamous non–small cell lung cancer (NSCLC) not harbouring EGFR or ALK genetic aberrations, as shown by the Phase III KEYNOTE-189 (NCT02578680).
Pembrolizumab (Keytruda®) as single-agent immunotherapy in the frontline setting of any histology NSCLC with a PD-L1 expression ≥1% was associated with improved overall survival (OS) when compared to platinum-doublet chemotherapy in the KEYNOTE-042.
There is no excerpt because this is a protected post.